CorMedix Therapeutics announced a definitive agreement to acquire most of Heron Therapeutics' assets for $145 million cash, 14.58 million shares, and up to $55 million in earn-outs/royalties. This is a significant M&A event for both companies, likely leading to a re-evaluation of their respective valuations and future prospects.
CorMedix Therapeutics is acquiring substantially all assets of Heron Therapeutics in a deal valued at $145 million in cash, 14,583,333 shares of CorMedix common stock, and up to $55 million in contingent earn-out payments and royalties. This is a major M&A event for both companies, signaling a significant strategic shift. For CorMedix, it represents an expansion of its asset base and potential market reach, which could be a long-term positive if the integration is successful. For Heron, divesting most of its assets while remaining publicly traded suggests a restructuring or pivot, providing immediate capital and a new direction. Traders should watch for immediate price reactions in both CRMD and HRTX as the market digests the terms and implications of this acquisition, with potential for volatility until the deal closes in Q1 2027.